Guerrasio A, Martinelli G, Ambrosetti A, Falda M, Paolino F, Rege-Cambrin G, Rosso C, Pignatti P F, Gasparini P, Perona G
Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Italy.
Haematologica. 1991 Mar-Apr;76(2):126-30.
The suppression of Ph1-positive hemopoiesis is a major goal in the treatment of CML; in this context the CML patients in blast crisis obtaining a complete clinical remission represent a useful model to investigate the behavior of the Ph1-positive and negative clones during bone marrow repopulation after ablative therapy.
Seven CML patients in blast crisis (four lymphoid and three myeloid) who obtained a complete clinical remission after an intensive polychemotherapy treatment were evaluated by cytogenetic and molecular analysis both in blast and remission phases. Standard cytogenetic and Southern techniques were employed; in addition, minimal residual disease status (MRD) was ascertained by amplification (PCR) of the specific bcr-abl chimeric transcripts.
After a single cycle of induction, all lymphoid cases displayed a complete restoration of Ph1-negative hemopoiesis; by contrast, one myeloid blast crisis showed a partial suppression of Ph1-positive hemopoiesis only after two cycles of chemotherapy, and in the remaining two cases the hematological remission was indeed a reversion to the chronic phase.
Ph1-positive chronic clones present in lymphoid blast crisis showed a higher degree of sensitivity to intensive chemotherapy than those present in the myeloid cases. This observation further suggests that the growth properties of the Ph1-positive clones are highly variable from case to case and probably tend to progress during the time-course of the disease.
抑制Ph1阳性造血是慢性粒细胞白血病(CML)治疗的主要目标;在此背景下,处于急变期且获得完全临床缓解的CML患者是研究清髓治疗后骨髓重建过程中Ph1阳性和阴性克隆行为的有用模型。
对7例在强化多药化疗后获得完全临床缓解的急变期CML患者(4例淋巴细胞型和3例髓细胞型)在急变期和缓解期进行细胞遗传学和分子分析评估。采用标准细胞遗传学和Southern技术;此外,通过特异性bcr-abl嵌合转录本的扩增(PCR)确定微小残留病状态(MRD)。
经过一个诱导周期后,所有淋巴细胞型病例均显示Ph1阴性造血完全恢复;相比之下,1例髓细胞型急变期病例仅在两个化疗周期后才显示Ph1阳性造血部分受抑制,而在其余2例中,血液学缓解实际上是向慢性期逆转。
淋巴细胞型急变期存在的Ph1阳性慢性克隆对强化化疗的敏感性高于髓细胞型病例中的克隆。这一观察结果进一步表明,Ph1阳性克隆的生长特性在不同病例间差异很大,并且在疾病进程中可能趋于进展。